NCT05461222招募中不适用
A Study of the Effectiveness of Fetal Endoscopic Tracheal Occlusion (FETO) in the Management of Severe Prenatally Diagnosed Congenital Diaphragmatic Hernia (CDH)
Yair Blumenfeld1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2023年4月17日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Number of neonates who survive until initial hospital discharge
研究概览
简要总结
The purpose of the study is to study the efficacy of fetal endoscopic tracheal occlusion (FETO) in cases of severe congenital diaphragmatic hernia (CDH). This study will also collect safety and effectiveness data for the off-label use of the FETO Goldballoon (the balloon that will be inserted into the fetal trachea), manufactured by Balt medical. The investigators hope to study the risks and benefits of FETO in cases of severe CDH in an advanced medical center such as Lucile Packard Children's Hospital (LPCH) Stanford with access to advanced maternal-fetal medicine, neonatal services, and neonatal ECMO, and pediatric surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Maternal Age: 18-50
- •Singleton gestation
- •Gestational age before 29 weeks 6 days
- •Severe left or right-sided CDH: For severe left sided CDH observed-to-expected lung-to- head ratio (o/e LHR) less than 25% between 22 and 29 6/7 weeks' gestation, liver herniation, MRI lung volumes less than 30% expected based on gestational age nomograms. For severe right sided CDH o/e LHR less than 30 % between 22 and 29 6/7 weeks' gestation, liver herniation, MRI lung volumes less than 30% expected based on gestational age nomograms.
- •Normal genetic karyotype or microarray testing by amniocentesis or chorionic villus sampling (CVS)
- •Absence of associated fetal structural cardiac anomalies by a dedicated fetal echocardiogram
- •Absence of other structural anomalies by ultrasound or MRI
- •Appropriate multi-disciplinary counseling performed with maternal-fetal medicine, neonatology, pediatric surgery, genetics, pediatric otolaryngology (ENT).
- •Must be willing to remain near LPCH Stanford (within 30 minutes from the hospital) for the duration of the balloon placement.
- •No maternal and/or fetal contra-indications to fetal surgery such as a bleeding disorder, poorly controlled diabetes or hypertension, short cervix (measuring < 20mm), risk for preterm birth etc.
- •Planned pregnancy surveillance at LPCH Stanford
- •Planned delivery at LPCH Stanford
- •Able to provide written consent
- •Willingness to comply with all study procedures and availability (meets psychosocial criteria) for the duration of the study including having a support person
排除标准
- •Contraindications to fetal surgery including poorly controlled hypertension, diabetes or other maternal medical condition including hematological disorder
- •High risk for preterm labor and/or delivery based on either significant history of preterm birth, short cervix (measuring < 20mm), significant uterine anomaly or other risk factor, incompetent cervix (requiring cerclage)
- •Non-isolated CDH - CDH with additional structural anomalies
- •Significant maternal obesity defined as a body mass index (BMI) greater than
- •BMI is a calculation which includes a person's height and weight
- •History of natural rubber latex allergy
- •Uterine anomaly such as large or multiple fibroids or mullerian duct abnormality
- •Participation in another intervention study that influences maternal and fetal morbidity and mortality.
- •Bilateral CDH, left-sided CDH with O/E LHR >25%, or left-sided CDH with O/E LHR <25% but liver completely down in abdomen
- •Right-sided CDH O/E LHR >30% or right-sided CDH with O/E LHR <30% with liver completely down in abdomen
- •Significant placental abnormalities (abruption, chorioangioma, accreta) known at the time of enrollment and/or surgery
- •Maternal-fetal Rhesus isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia, affecting the current pregnancy.
- •Maternal HIV, Hepatitis B with positive surface antigen, Hepatitis C with presence of virus in maternal blood due to risk of fetal transmission during the procedure
- •No safe or feasible fetoscopic approach to balloon placement.
研究组 & 干预措施
Fetal Endoscopic Tracheal Occlusion (FETO)
Experimental
FETO is performed in-utero and the balloon is removed prior to delivery, and children will have follow-up visits until the age of 2
干预措施: Balt "Goldballoon" (Device)
结局指标
主要结局
Number of neonates who survive until initial hospital discharge
时间窗: Average approximately 6 months (up to 1 year)
次要结局
- Number of children who survive until 2 years of age(2 years)
- Number of children who survive until 6 months of age(6 months)
- Number of neonates who survive until 28 days of life(28 days)
- Number of children who survive until 1 year of age(1 year)
- Number of children who receive extracorporeal membrane oxygenation (ECMO)(Average approximately 6 months (up to 1 year))
研究者
Yair Blumenfeld
Associate Professor
Stanford University
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)Pulmonary HypoplasiaPulmonary Artery HypertensionCongenital Diaphragmatic HerniaNCT03138863Rodrigo Ruano10
已完成
不适用
Fetoscopic Endoluminal Tracheal Occlusion (FETO) With Smart-TOCongenital Diaphragmatic HerniaNCT04931212Assistance Publique - Hôpitaux de Paris23
招募中
不适用
Fetoscopic Endoluminal Tracheal OcclusionCongenital Diaphragmatic HerniaNCT03674372University of Colorado, Denver10
招募中
不适用
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic HerniaCongenital Diaphragmatic HerniaNCT05962346Mauro H. Schenone20
撤回
不适用
Fetal Endotracheal Occlusion (FETO) in Fetuses With Severe Congenital Diaphragmatic HerniaCongenital Diaphragmatic HerniaNCT06281717Eyal Krispin10